With 1 million new cases and 200,000 children dead each year, Tuberculosis (TB) is now the leading cause of death from infectious diseases for children of all ages globally (UNICEF). ImproViTB is among the first pediatric clinical studies in the Central African region aimed at improving the clinical outcome and quality of life of children with pulmonary tuberculosis through a standard antituberculosis treatment supplemented with vitamin D.
This project is lead by a consortium of research institutions and universities from 4 Central African countries (Republic of Congo, Democratic Republic of Congo, Cameroon and Gabon) and 3 European countries, coordinated by CANTAM (Prof. Francine Ntoumi), the Network of Excellence in clinical research for Central African region.

Tags:

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore More

INTEGRATION

“This project will improve malaria prevention strategies for both children, pregnant women and families as a whole as the study is being conducted in families which will raise awareness of

Read More

Exemplary coordination of African researchers and scientists

Exemplary coordination of African researchers and scientists involved in the response to the pandemic to study treatments that prevent serious complications of COVID-19 https://bit.ly/37SvaCz

Read More

From 2003 at the forefront of supporting Sub-Saharan Africa’s response to poverty-related infectious diseases, EDCTP plays a key role also in the African response to Covid-19

The European & Developing Countries Clinical Trials Partnership (EDCTP) is a public-public partnership between countries in Europe and sub-Saharan Africa, supported by the European Union, which since 2003 has been

Read More